

HEALTHCARE SECTOR BULLETIN

Issue 5: June 2014



HEALTHCARE TRENDS & IMPACT STORIES

Country: Indonesia

Headline: **Maximize the fresh opportunities for healthcare distribution in the fast-growing Indonesian provinces to boost services for principals and consumers**

Summary: Government decentralization has increased the flow of funds to provinces that were previously being left behind, often in spite of the fact that some of those provinces were key sources of the nation's wealth, such as coal, oil and gas, timber and palm oil. Now these provinces are finally starting to benefit from having a greater share of government funds and this is being reflected in comparative growth figures.

The consequence for the healthcare sector is that growth will continue to be higher in the provinces as consumer purchasing power increases in those regions at a rate greater than in the major cities. In turn this will require greater attention to the provinces for achieving the desired availability of medicines and, in the case of consumer health products, more visibility.

Link: <http://www.zuelligpharma.com.sg/sites/default/files/MP53%20Feature%20Story.pdf>

Country: Asia

Headline: **Hospital companies prepare to meet surging demand for health care in Asia**

Summary: Although Asia's emerging economies are slowing, the rise of their middle classes is continuing. In Indonesia the number of middle- and upper-income consumers is expected to swell from 74m in 2013 to 141m by 2020, predicts the Boston Consulting Group. Rising incomes mean rising demand for health care. The average Chinese city-dweller's health spending more than doubled between 2002 and 2010, estimates PwC, a firm of consultants.

Governments are trying to meet this demand. Malaysia and Thailand already have broad public health-care systems. China, which boasts that it has extended basic medical coverage to 97% of its people, continues to make reforms. The Philippines is in the midst of a rapid expansion of insurance. Indonesia is in the first year of a plan to bring health coverage to the entire population by 2019.

However, in many countries hospital beds are in short supply. Indonesia has only nine for every 10,000 people and the Philippines ten. America and Britain each have 29. And the quality of public hospitals varies greatly. Governments throughout the region say they will open more hospitals. But private operators think there will be a continuing shortfall for them to fill.

Link: <http://www.economist.com/news/business/21602220-hospital-companies-prepare-meet-surg-ing-demand-health-care-asia-call>

HEALTHCARE SECTOR NOTABLE TRANSACTIONS

Country: Indonesia

Headline: **Mayapada Hospitals to Acquire Control of Prima Healthcare**

Summary: Sejahteraraya Anugrahjaya, the operator of Mayapada Hospitals, is set to buy control of Prima Healthcare Solutions, a medium-size clinic operator in Jakarta, as part of its expansion plans this year.

The company will acquire 90 percent stake at Prima Healthcare, established in April last year. Prima operates a clinic chain under the Your Clinic brand.

Prima has six clinics that offer medical checkups and consultations as well as X-ray facilities and laboratory services, in Kelapa Gading, North Jakarta; Mayapada Tower 2 in Central Jakarta; Taman Palem Lestari in Pine Hills and Tanjung Duren, both in West Jakarta.

Links: <http://www.thejakartaglobe.com/business/mayapada-hospitals-acquire-control-prima-healthcare/>

Country: India

Headline: **ChrysCap sells 12.5% in Intas for Rs 1,100cr (USD 170m)**

Summary: Singapore investor Temasek has bought 12.5% stake in Intas Pharmaceuticals, one of India's top 10 drug makers by sale, for a little over Rs 1,100 crore (\$170 million), people directly involved with the development said.

The deal is a secondary share purchase from ChrysCapital - translating to a 24 times profit for the latter - and is one of the best gains reported by any private equity investor of scale in India. ChrysCapital, the largest India focused private equity investor, had invested Rs 50 crore (\$11 million) for the initial 12.5% in 2004. Temasek's share acquisition valued the Ahmedabad-based Intas at Rs 8,800 crore, or \$1.5 billion.

Links: <http://timesofindia.indiatimes.com/business/india-business/ChrysCap-sells-12-5-in-Intas-for-Rs-1100cr/articleshow/35966214.cms>

Country: Philippines, Singapore

Headline: **MPIC hospital unit eyes Asean expansion**

Summary: The healthcare group of Metro Pacific Investments Corp. (MPIC) and its Singaporean sovereign wealth fund partner are looking at establishing a presence in Southeast Asian neighbors in the coming years even as the hospital chain continues to strengthen its market leadership locally.

The overseas expansion will cater to the needs of the developing healthcare sector in the region while taking advantage of possible synergies with other MPIC businesses also going abroad, an executive said last week.

Links: <http://www.philstar.com/business/2014/06/02/1329928/mpic-hospital-unit-eyes-asean-expansion>

Country: Indonesia

Headline: **Mensa Group in talks with foreign investors for its finished products business**

Summary: Menjangan Sakti (Mensa) Group, an Indonesian, pharmaceuticals and healthcare company, is in talks with foreign investors for its finished products business, Director Jonathan Sudharta said. The new policy introduced by the government of Indonesia in 2008 requires the foreign players to manufacture locally and this has been getting more and more stringent with each year, so the foreign players need to invest or acquire local manufactures.

The new policy made Mensa Group invest in its own manufacturing arm, though it traditionally relied on importing and distribution. The finished products subsidiaries include Otto Pharma and Landson. Otto manufactures tablets, capsules, syrup, dry syrup, creams, sachets of oral and injectable products.

Links: Mergermarket

TRANSACTION NEWS

Date	Headlines	Summary
9-Jun	<i>Genero looks for partners to introduce new dermatology products in Indonesia (Source: Mergermarket)</i>	Genero, a private pharmaceutical service unit of Indonesia-based Arya Noble Group, plans to invite companies currently developing their own dermatology products to form a partnership. The partnership could be a joint venture (JV) to help the company introduce more products into the local market.
9-Jun	<i>Nectar Lifesciences up for sale (Source: The Economic Times)</i>	The owners of Nectar Lifesciences (NLL), an Indian, Chandigarh-based pharmaceuticals company, are planning to sell the company, The Economic Times reported. The owners, identified as Sanjiv Goyal and family, intend to sell their combined 44.35% holding in NLL, along with an 11.59% stake in the company held by private equity (PE) fund New Silk Route (NSR).
9-Jun	<i>Vasan Healthcare being eyed for takeover by Netcare, IHH, and others (Source: Business Standard)</i>	Vasan Healthcare, an India-based dental and eye care hospitals operator, is being eyed for possible acquisition by multiple suitors, including Netcare, a private hospital chain based in South Africa, the Business Standard reported. As per the report, Netcare was holding talks with unnamed private equity (PE) funds and existing shareholders in Vasan Healthcare for acquiring a majority stake in the Indian company. Malaysia-based Integrated Healthcare Holdings (IHH) has also shown interest in acquiring Vasan Healthcare, sources added. The deal has an expected value of between INR 45bn-INR 50bn (USD 848.15m).
9-Jun	<i>Nova Medical Centers seeks opportunities of acquisition for IVF unit in Middle East, Bangladesh, Sri Lanka (Source: VCCircle)</i>	Nova Medical Centers, which runs surgical centres and a chain of in-vitro fertilisation (IVF) centres in India, is seeking opportunities of acquisition for its IVF unit in the Middle East, Bangladesh and Sri Lanka.
9-Jun	<i>Sysmex, Toppan Printing to cooperate in genetic analysis testing, invest in Riken Genesis (Source: Sysmex Press Release)</i>	Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and Toppan Printing (HQ: Tokyo, Japan; President & Representative Director: Shingo Kaneko) have entered into an agreement to cooperate for advancement in the genetic analysis testing industry, and to invest in Riken Genesis, a Toppan Printing subsidiary. The companies will accelerate their approach to personalized medicine by fostering their technological synergies. In personalized medicine, gene detection technologies and bioinformatics are playing an important role in providing the most appropriate medical care to respective patients.
8-Jun	<i>Sejahteraya Anugrahjaya to acquire 90% stake in Prima Healthcare Solution (Source: Kontan)</i>	Sejahteraya Angurahjaya, the listed Indonesian hospital management group, is planning to acquire a 90% stake in Prima Healthcare Solution, an Indonesian health management company, Kontan reported.
7-Jun	<i>Fosun International in pharmaceutical products logistics</i>	Fosun International, the listed China-based diversified company, has signed a framework agreement with listed pharmaceutical products distributor Sinopharm

JV with Sinopharm (Source: Sing Tao Daily)

Group to set up a JV company. The JV will invest USD 500m – USD 1bn to build a nationwide pharmaceutical products logistics network in China in the next three to five years. Fosun International will hold a 60% stake in the JV while Sinopharm will hold the other 40%, the report noted.

6-Jun	<p><i>Sinopharm Group to sell 35% stake in Sinopharm Holding Medical Investment Management (Source: Chinese Equity Exchange Announcement)</i></p>	<p>Sinopharm Group [Guo Yao Kong Gu] (1099.HK) has put 35% stake in Sinopharm Holding Medical Investment Management [Guo Yao Kong Gu Yi Liao Tou Zi] up for sale with a bidding window of 20 working days, according to an announcement posted on the Shanghai United Assets and Equity Exchange. The initial bidding price is CNY 175m (USD 27.978m). Sinopharm Group, a China-based, Hong Kong-listed pharmaceutical company, currently holds a 100% stake in Sinopharm Holding Medical Investment Management. Sinopharm Holding Medical Investment Management, a Shanghai-based company, is engaged in investing and managing hospitals. It has a registered capital of CNY 500m.</p>
6-Jun	<p><i>Lyka Labs founding family reviews stake sale options to establish plant (Source: Mergermarket)</i></p>	<p>Lyka Labs [BOM: 500259], a Mumbai, India-based pharmaceuticals company, is reviewing options to offload a stake to bring in funds into the company to set up a lyophilised injection plant, said a source with knowledge of the company strategy. The company could raise funds to the tune of INR 360m (USD 6m) to INR 400m.</p>
6-Jun	<p><i>Shenzhen Josen Industrial sold to Anhui Saunaking for CNY 108m (Source: Shenzhen Stock Exchange)</i></p>	<p>Anhui Saunaking [San Na Jin, 300247.SZ], a listed Chinese healthcare electrical appliances maker, has inked an agreement to buy the 100% stake in Shenzhen Josen Industrial [Zhuo Xian Shi Ye] for CNY 108m (USD 17.3m).</p>
6-Jun	<p><i>Ramsay expected to extend due diligence for Generale de Sante (Source: The Australian)</i></p>	<p>Ramsay, the ASX-listed hospital owner, is anticipated to prolong its exclusive due diligence for French hospital operator Generale de Sante, The Australian reported on Friday, 6 June.</p>
6-Jun	<p><i>Fertility Associates seeking JV partners in Asia to expand IVF business (Source: Mergermarket)</i></p>	<p>Fertility Associates, a privately held New Zealand-based IVF company, is actively seeking joint venture partners for Asian expansion, CEO Alex Price said. The company, which has annual revenues of NZD 30m (USD 25.5m), is looking at a number of opportunities at the moment, he noted. Fertility Associates opened its first Asia clinic in Malaysia this year with joint venture partner Qualitas Medical Group, a Malaysia-based primary health care provider. It is looking for similar opportunities in other markets with critical mass, like India and China, Price said.</p>
5-Jun	<p><i>Jilin Yatai likely to conduct M&As in pharmaceutical sector</i></p>	<p>Jilin Yatai (Group) (Ya Tai Ji Tuan) [600881.SH], a Jilin, China-based listed building materials company, is likely to conduct M&As in the pharmaceutical sector, the Chinese-language Shanghai Securities News reported on 5 June. The targets of acquisition likely include anti-tumor drugs, biopharmaceutical products, Chinese medicine, healthcare products, retailer chain business and online retailing companies, especially those with competitiveness in niche market or those that can complement the sales network of Jilin Yatai. Jilin Yatai reported operating revenues of CNY 13.1bn (USD 2.1bn) in 2013, CNY 927m of which was contributed</p>

5-Jun	<i>Darya Varia Laboratoria draws interest from US pharma company (Source: Investor Daily)</i>	Indonesia-listed pharmaceuticals company Darya-Varia Laboratoria, has drawn the interest of a potential foreign suitor, reported the Investor Daily. The report, which cited market rumors, noted that an unidentified US-based pharmaceutical company, is planning to acquire an unspecified stake in Darya-Varia. Darya-Varia has a market cap of IDR 2.35tn (USD 197m).
5-Jun	<i>Shanghai Sine Wanxiang Pharmaceuticals' 16% stake puts up for sale (Source: Chinese Equity Exchange Announcement)</i>	A 16% stake in Shanghai Sine Wanxiang Pharmaceuticals [Shang Hai Xin Yi Wan Xiang Zhi Yao] has been put up for sale with a bidding window of 20 working days, according to a 5 June announcement posted on the Shanghai United Assets and Equity Exchange. The initial bidding price is CNY 36.96m (USD 5.908m) and the vendors are 16 state-owned organizations, including health centers, hospitals and a pharmaceutical company. Shanghai Sine Wanxiang Pharmaceuticals, a pharmaceutical company, has a registered capital of CNY 100m. According to an evaluation, the company had net assets of CNY 231m, as of 30 June 2013.
5-Jun	<i>Takshasila Hospitals to get USD 10.6m investment from JBIC (Source: Business Standard)</i>	Japan Bank for International Cooperation (JBIC) has agreed to the issue and subscription of preferred stocks through a third party allocation for Takshasila Hospitals Operating Private Limited, a general hospital business in Bangalore, the capital of southwestern Indian state of Karnataka. The company is being jointly operated by three investors: Secom Co., Ltd., subsidiary Secom Medical System Co., Ltd., Toyota Tsusho Corporation [TYO:8015], and Kirloskar Group, a major Indian conglomerate. This is the first time for JBIC to invest in the medical business, with an investment amount of INR 630m (USD 10.6m). Focusing on disorders of the cranial nervous system, cardiac system, and digestive system, this 294 bed general hospital has high-precision medical equipment capable of a high level of acute medical care to support hospitalization and surgery.
5-Jun	<i>Microskin seeking cornerstone investor and auditor for Frankfurt IPO (Source: Mergermarket)</i>	Microskin, an Australian skin technology company, is keen to secure a cornerstone investor for its upcoming listing on the Frankfurt Stock Exchange in eight weeks, said chairman Barry Amor. An ideal cornerstone investor could be a company that is already involved in the cosmetic industry but is interested in getting into the specialized skin camouflage space, or companies already in the space looking to enhance their offerings.
5-Jun	<i>Peptron in advanced talks to out-license diabetes treatment; IPO filing in August (Source: Mergermarket)</i>	Peptron, a privately held South Korean peptide developer, is in advanced talks with a global pharmaceutical firm to out-license diabetes treatment PT-302, two sources familiar with the situation said. It expects to close the deal as soon as the end of 2014 or early next year, they noted.
5-Jun	<i>Lijun International Pharmaceutical's substantial shareholder to sell approximately 26.28% company's issued share capital through placement (Source: HKEX)</i>	Lijun International Pharmaceutical [HKEX:2005] announced that a substantial shareholder has agreed to sell approximately 26.28% of the company's issued share capital through a placement.

4-Jun	<i>SeQuent Scientific looking for acquisitions (Source VCCircle)</i>	SeQuent Scientific, the India-based drug company, is on the lookout for potential overseas as well as Indian acquisition targets, reported VCCircle. SeQuent Scientific is targeting a four-fold growth in the size of its veterinary business that is currently at between INR 2.5bn (USD 42.2m) and INR 3bn.
4-Jun	<i>Epsilon Pharmaceuticals INR 1bn acquisition by Amneal Pharmaceuticals at stage of advanced talks (Source: Business Standard)</i>	Amneal Pharmaceuticals, a US-headquartered drug manufacturer, is now in advanced talks to acquire Epsilon Pharmaceuticals, an Indian oncology products maker based in Hyderabad, Business Standard reported. It was also reported that the deal may be valued at INR 800m-INR 1bn (USD 13.5m-USD 16.9m).
4-Jun	<i>Bushu Pharmaceuticals' private equity owner retains Nomura for sale (Source: Mergermarket)</i>	Japanese private equity firm Tokio Marine Capital (TMCap) has retained Nomura Securities as sellside advisor for an upcoming sale of portfolio company Bushu Pharmaceuticals, a Saitama-based contract manufacturing organization (CMO), according to people familiar with the situation.
4-Jun	<i>Kangmei Pharmaceutical gets EGM approval to raise CNY 6bn via preferred shares issue (Source: Shanghai Stock Exchange)</i>	Kangmei Pharmaceutical [Kang Mei Yao Ye, 600518.SH], a listed Guangdong-based pharmaceutical company, said in a stock exchange announcement dated 4 June that its EGM held on 3 June approved to raise up to CNY 6bn (USD 962.4m) via an issuance of preferred shares.
4-Jun	<i>Jingdezhen Fuxiang Pharmaceutical aims to raise CNY 241m via ChiNext IPO (Source: CSRC)</i>	Jingdezhen Fuxiang Pharmaceutical (Fushine) [Fu Xiang Yao Ye], a Jiangxi-based, privately held pharmaceutical company, aims to raise approximately CNY 241m (USD 38.5m) through a ChiNext initial public offering. The proceeds will be used to finance production, R&D and replenish working capital and repay bank loans.
4-Jun	<i>Healthscope expected to release sellside research in two weeks' time (Source: Australian Financial Review)</i>	Healthscope, the Australian hospital business, is expected to release sellside research in two weeks' time, the Australian Financial Review reported. According to the unsourced report in the paper's Street Talk column, publication of the research will fuel speculation that Healthscope's owners, TPG and Carlyle, will embark on an IPO as their preferred means of exit.
4-Jun	<i>Shanghai Kindly Enterprise Development expects to raise CNY 789.658m via Shanghai IPO (Source: CSRC)</i>	Shanghai Kindly Enterprise Development [Kang De Lai], a privately held medical devices company, is expecting to raise CNY 789.658m (USD 126.33m) via an initial public offering on the Shanghai Stock Exchange. The proceeds will be invested in two medical devices production projects.
4-Jun	<i>Samsung Medison rumored to go public (Source: Korea Economic Daily)</i>	Samsung Medison, an unlisted South Korean medical equipment developer and a business unit of Samsung Group, is rumored to go public, reported the Korea Economic Daily. Samsung Medison recorded sales of KRW 250.6bn (USD 244.7m) last year. Listed Samsung Electronics has a 68.45% stake in Samsung Medison.

4-Jun	<i>Bionaturis in talks with two targets, will make further acquisitions (Source: Mergermarket)</i>	Bionaturis [MCE BNT], the Spanish biopharmaceutical company, is in talks with two targets and will make more acquisitions this year and next, CEO Victor Infante said. The company has signed a Memorandum of Understanding one target and it is in very advanced talks with a second, the executive said. The company is working with advisors but he declined to provide more details. The transaction value would be between EUR 8m and EUR 10m, Infante added. Bionaturis has expertise in producing tailor-made biologics at industrial scale and is focused on developing compounds for niche diseases and for veterinary applications. The company is interested in pursuing further acquisitions.
4-Jun	<i>Nippon Shokubai has JPY 50bn (USD 488m) prepared for M&A in medical and healthcare sector (Source: Nikkan Kogyo Shimbun)</i>	Nippon Shokubai, the listed Japan-based chemical manufacturer, has JPY 50bn (USD 488m) prepared for M&A in the medical and healthcare sector
3-Jun	<i>Granules India opportunistic about acquisitions aimed at expanding product portfolio (Source: Mergermarket)</i>	Granules India [BOM:532482], a generic pharmaceuticals company, is opportunistic about acquisitions of active pharmaceutical ingredient (API) and formulation manufacturing plants. The key reason for the company's acquisitions would be to diversify and expand its product portfolio. The company acquired Hyderabad-based Auctus Pharma for INR 1.2bn (USD 20m) in November 2013, adding 12 API products to its portfolio, bringing the total to 17.
3-Jun	<i>Town Health International will speed up pace of making acquisitions this year and next year (Source: Infocast News)</i>	<p>Town Health International, a Hong Kong-listed healthcare services provider, will speed up its pace of making acquisitions this year and next year, Infocast News reported. The Chinese language news report, citing CEO Cho Kwai Chee, said potential takeover targets include profitable pharmaceutical businesses, and the potential deal value would be around 5x of the target's EBITDA, or 10x – 12x of its price-to-earning ratio (P/E). Town Health International will have a capital expenditure of approximately HKD 600m (USD 77.4m) – HKD 700m this year, he added.</p> <p>Separately, Town Health announced that it has signed an investment framework agreement for the possible investment of a 51% stake in Renji BVI Company for CNY 153m (USD 24.5m). Town Health International hopes to take advantage of the possible investment and, if it materializes, to develop a PRC hospital platform engaging in a business model of reforming public hospitals in the Zhejiang Province.</p>
3-Jun	<i>j1.com raises CNY 300m from SIGVC in Series A round of fundraising (Source: China Business News)</i>	j1.com [Jian Yi Wang], a Shanghai-based online pharmaceutical products retailer, has raised CNY 300m (USD 47.97m) in its Series A round of fundraising, based on information provided by the company. The company has received the first batch payment of CNY 110m and the investor is Shanghai-based SIGVC. The funds will be used to fund its data management center and call center construction. j1.com is expecting to have sales of CNY 10bn in about four years.
3-Jun	<i>CAS Capital looking to raise JPY 15bn for its new No.6 fund by late June (Source: Mergermarket)</i>	CAS Capital, a Japan-based, private equity (PE) firm, is looking to raise JPY 15bn (USD 150m) for its new CAS Capital Fund No.6, with its final close scheduled for late June this year, the firm's founding partner and Representative Director Haruo Kawamura said. The firm had already announced the first close for its new fund this February.

3-Jun	<i>Shanghai Yaoji Playing Card signs framework agreement to buy 22% stake in Shanghai Cell Treatment Engineering Research Center (Source: Shenzhen Stock Exchange)</i>	Shanghai Yaoji Playing Card [Yao Ji Pu Ke; SZ: 002605], a China-based listed playing cards maker, has signed a framework agreement to acquire a 22% stake in Shanghai Cell Treatment Engineering Research Center through a capital increase of CNY 130m (USD 21m), according to a stock exchange announcement. The target is a domestic cell therapy technologies R&D, cell production and cell therapy clinical applications center operator.
2-Jun	<i>Kwang Dong Pharmaceutical decides not to bid for Dream Pharma (Source: VCCircle)</i>	Kwang Dong Pharmaceutical, a listed South Korean company, said in a stock exchange statement that it has decided not to bid for Dream Pharma. In a disclosure issued as an update to the matter, Kwang Dong said it will not participate in the round of binding bids. Dream Pharma is the generic development unit of Hanwha Chemical, and Kwang Dong Pharmaceutical earlier announced it was in talks with a company that had submitted a letter of intent in the sale of Dream Pharma, to form a consortium to bid. An earlier report estimated the sale could fetch KRW 200bn (USD 192.2m).
2-Jun	<i>Autotelic to launch USD 22m fundraise for drug-device combination approval and China entry (Source: Mergermarket)</i>	Autotelic, a private Fountain Valley, California- based medical device company, is undertaking a USD 22m fundraise in the next six to 12 months. The Series A financing worth USD 2m will be followed by a USD 20m listing on the OTC Bulletin Board exchange in the US about six months later. This will be in the form of a private placement with multiple institutional investors including mutual and hedge funds.
1-Jun	<i>Alltech may dispose of life-sciences unit for USD 1bn-plus; planning future acquisitions in China (Source: Irish Independent)</i>	Alltech, the family-owned biotech, brewing and animal-nutrition group headquartered in Nicholasville, Kentucky, could divest its life-sciences operation. Alltech founder Pearse Lyons said that Alltech is planning future acquisitions in China, which has very good opportunities, the item reported. He said the company has a EUR 150m annual spend earmarked for acquisitions, as long as they are a good fit for the business. He added that in the event of a larger deal coming up, in the region of EUR 400m-1.2bn,
31-May	<i>Gmax Biopharm to initiate USD 10m fundraise to progress GPCR-targeting antibody therapeutics (Source: Mergermarket)</i>	Gmax Biopharm [Hongyun Hua Ning Shengwu Yiyao Gongcheng Youxian Gongs] is in talks with investors to initiate a USD 10m Series A financing round, said Chief Executive Officer and founder Shuqian Jing. The money will be used to advance its preclinical GPCR-targeted monoclonal antibodies.
31-May	<i>Sichuan Medicine's 17.5% stake put up for sale at initial bidding price of USD 40m (Source: Southwest United Equity Exchange)</i>	A 17.5% stake in Sichuan Medicine [Si Chuan Yi Yao Gu Fen] has been put on the block at an initial bidding price of CNY 253m (USD 40.5m), according to an announcement posted on the Southwest United Equity Exchange. Sichuan Medicine is a China-based state-controlled pharmaceutical distribution company. According to the company's annual report, it had revenue and net profit of CNY 4.14bn and CNY 98m, respectively, last year.
30-May	<i>Shanghai Fenghua Group in talks over buying 100% of Jilin Beisha</i>	Shanghai Fenghua Group [Feng Hua Gu Fen; SH: 600615], a China based listed real estate developer, said in a stock exchange announcement on 30 May that it is planning to acquire 100% of Jilin Beisha Pharmaceutical [Bei Sha Yao Ye], a Jilin-based privately held pharmaceutical company. Currently, the listed company and its owner of controlling interest Loncin Holding [Long Xin Kong Gu] are in talks with the

	Pharmaceutical (Source: Shanghai Stock Exchange)	shareholders of Jilin Beisha Pharmaceutical over the deal details and no restructuring plan has been worked out so far.
30-May	<i>Phylogica considers options to divest non-core assets to focus on intra-cellular drug platform (Source: Mergermarket)</i>	Phylogica (ASX:PYC; XETRA:PH7), an Australian peptide drug discovery company, is assessing opportunities to divest four non-core assets to focus on its core proprietary intra-cellular drug discovery and delivery platform.
30-May	<i>Virtus acquires majority stake in Sims IVF for EUR 15m</i>	Virtus Health (ASX: VRT) is pleased to announce that it has acquired a 70% interest in Ireland's largest IVF provider SIMS IVF for EUR 15.49m (cash free/debt free basis). SIMS IVF is a pioneer in the delivery of IVF services in Ireland and undertakes approximately 25% of Ireland's IVF services from its state-of-the-art facility in Dublin. For the 12 months to 31 December 2013, SIMS IVF generated revenue and maintainable EBITDA of EUR 12.44m and EUR 2.85m respectively.
30-May	<i>DuoBack Korea targeting medical device expansion in strategy shift (Source: Mergermarket)</i>	DuoBack Korea, a listed South Korea-based furniture maker, is focusing on designing and growing a medical device business as part of a strategic diversification. The company aims to complete R&D and design the structure of the business by the end of the year.
30-May	<i>Elang Mahkota Teknologi gets USD 50m loan from Standard Chartered Private Equity for medical business investments (Source: Kontan)</i>	Elang Mahkota Teknologi (EMTK), the listed Indonesian media company, has signed an investment agreement with Standard Chartered Private Equity for a USD 50m facility for planned investments in the medical sector. The funds will be used by EMTK's hospital management unit -- Emtek Medika Corpora -- to expand its business, including via acquisitions. The report noted that EMTK expects to see a IDR 200bn (USD 17.2m) per year revenue contribution from its hospital management business.
29-May	<i>Sino Biopharmaceutical will look for opportunities to acquire pharmaceutical companies and hospitals in China (Source: Hong Kong Economic Times)</i>	Sino Biopharmaceutical, the Hong Kong-listed biopharmaceutical products company, will look for opportunities to acquire pharmaceutical companies and hospitals in China.
29-May	<i>Yifeng Pharmacy expects to raise CNY 811.83m via Shanghai IPO (Source: CSRC)</i>	Yifeng Pharmacy [Yi Feng Da Yao Fang], a Hunan-based privately held pharmacy, is expecting to raise CNY 811.83m (USD 130m) from an initial public offering on the Shanghai Stock Exchange. It plans to sell up to 40m shares via the IPO, 16m of which will be disposed of by its existing shareholders, including its PE investor Capital Today Investment [Jin Ri Zi Ben]. The proceeds will be invested in marketing network expansion projects.
29-May	<i>Aster DM Healthcare gets USD 60m from existing investors IVFA and Olympus Capital, talks are on for</i>	Aster DM Healthcare, an India-based healthcare company, has raised USD 60m from existing investors India Value Fund Advisors (IVFA) and Olympus Capital. According to its Chairman Azad Moopen, Aster DM Healthcare wants to close a deal worth INR 500m-INR 1bn (USD 16.97m), and plans to add another 1,000 beds through acquisition in the next two years.

making an acquisition (Source: VCCircle)

<p>29-May <i>Shanghai Tofflon Science and Technology seeks to buy manufacturers of pharmaceutical machinery and medical devices (Source: China Business News)</i></p>	<p>Shanghai Tofflon Science and Technology (Tofflon) (Dong Fu Long) [300171.SZ], a Shanghai, China-based listed pharmaceutical freeze dryer maker and seller, is seeking to buy manufacturers of pharmaceutical machinery and medical devices.</p>
<p>28-May <i>Meihua Holdings signs agreement to acquire Shanxi Guangsheng Pharmaceutical Packaging's 52% stake (Source: Shanghai Stock Exchange)</i></p>	<p>Meihua Holdings Group [Mei Hua Ji Tuan; SH: 600873], a China-based amino acids and seasoning products maker, announced that one of its fully-owned subsidiaries signed a formal agreement to acquire around 52% stake in Shanxi Guangsheng Pharmaceutical Packaging [Guang Sheng Yi Yao Bao Zhuang] via a stake purchase and capital increase.</p>
<p>28-May <i>Akums Drugs and Pharmaceuticals eyeing private equity capital raise (Source: Mergermarket)</i></p>	<p>Akums Drugs and Pharmaceuticals, a New Delhi, India-based pharmaceuticals contract manufacturer, is in the market to raise private equity funding. The deal size would be in the range of INR 1bn (USD 17m) to INR 1.5bn and the proceeds are likely to be used for expansion. The family owned company has been valued at more than INR 10bn</p>
<p>28-May <i>Guangzhou Boji files ChiNext IPO application with CSRC, aims to raise CNY 244.5m (Source: CSRC)</i></p>	<p>Guangzhou Boji Medical & Biotechnological [Bo Ji Yi Yao], a privately held new-drug R&D outsourcing service provider, has filed a new ChiNext IPO application with the China Securities Regulatory Commission (CSRC), according to the CSRC website. According to the company's IPO prospectus published at the CSRC website, the company envisages IPO proceeds of approximately CNY 244.5m (USD 39m), which will be used to enhance clinical research, pharmaceutical research and assessment, and replenish operating funds for other main business-related areas</p>
<p>28-May <i>DomusVi attracts interest from China's Hanfor (Source: Les Echos)</i></p>	<p>DomusVi, the French elderly nursing homes operator, is understood to have attracted the interest of Hanfor, its partner in China. The current shareholders of DomusVi target a EUR 600m valuation for the company, which posted EUR 647m turnover and EUR 60m EBITDA last year, the report said.</p>
<p>28-May <i>Ebix acquires Healthcare Magic for USD 6m plus USD 12.5m potential earn out (Source: Ebix press release)</i></p>	<p>Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of on-demand software and e-commerce services to the insurance, finance and healthcare industries, announced yesterday that it has acquired Healthcare Magic, a medical advisory service with an online network of approximately 15,000 general physicians and surgeons spread across 50 specialties including alternative medicine.</p>
<p>27-May <i>Laurus Labs stake of maximum of 25% to be acquired by Warburg</i></p>	<p>Warburg Pincus, the private-equity player, has entered a deal to buy a maximum of 25% holding in Laurus Labs, the India-based drug ingredient manufacturer, for USD 125-USD 150m.</p>

<p><i>Pincus for USD 125-USD 150m (Source: The Economic Times)</i></p>	
<p><i>27-May Alves Group of Companies seeks investors for USD 8.5m fundraise (Source: Mergermarket)</i></p>	<p>Alves Group of Companies, a Mumbai, India based healthcare manufacturing group, is raising around INR 500m (USD 8.5m) through an equity stake sale to expand its medical devices division.</p>
<p><i>27-May BeiGene to raise USD 30-50m financing, garners pre-IPO investor interest (Source: Mergermarket)</i></p>	<p>BeiGene, a private Beijing-based drug developer focused on immuno-oncology, is actively raising USD 30-50m in financing, Chief Executive Officer John Oyler said. The investment would be in exchange for a minority stake in the company which is majority owned by Oyler and a number of undisclosed business angels in equal proportions</p>
<p><i>27-May Padman Health Care to be acquired by Quadrant Private Equity (Source: The Australian)</i></p>	<p>Padman Health Care, the Australian aged care operator, is to be acquired by Quadrant Private Equity, reported The Australian, without identifying sources. According to the report, Quadrant has confirmed the acquisition of Padman Health Care and will seek to merge it with its own aged care operator Estia Health, which is planned for a listing on the ASX this year. Quadrant acquired a majority stake in Estia for AUD 90m October 2013.</p>
	<p>South Australia-based Padman Health Care is the largest operator of residential health care in South Australia and Queensland. The company presently has 1100 beds under management in Victoria.</p>
<p><i>27-May Perfint Healthcare to look at raising between USD 40m and USD 50m within a few months (Source: Business Standard)</i></p>	<p>Perfint Healthcare, the India-based medical-devices company, will look at raising between USD 40m and USD 50m within a few months, reported the Business Standard. A sum of USD 32.7m was earlier raised by Perfint Healthcare in four venture funding rounds, with leading investors like IDG Ventures, Norwest Venture Partners and Accel India Ventures participating, the newspaper noted.</p>
<p><i>27-May Krishna Institute of Medical Sciences in advanced talks to get fresh investment (Source: VCCircle)</i></p>	<p>India-based Krishna Institute of Medical Sciences (KIMS) is engaged in advanced talks to get a fresh investment, reported VCCircle. The report cited two undisclosed sources as saying it is likely that KIMS will seal the deal for about INR 3.2bn (USD 54.5m). The transaction is currently at the stage of due diligence and may happen soon</p>
<p><i>27-May Xizi United to enter medical device industry via M&A (Source: Mergermarket)</i></p>	<p>Xizi United Holdings Co. [Xi Zi Lian He Kong Gu], a Hangzhou-based private conglomerate, is planning to enter the medical device industry through acquisitions and is screening potential targets in China.</p>
<p><i>26-May Globetronics Technology plans to acquire electronic medical manufacturers (Source: The Star)</i></p>	<p>Globetronics Technology, the Malaysia-listed integrated circuit contract manufacturer, is planning to acquire electronic medical manufacturers to increase its revenue, The Star reported. The report, citing Group Chief Executive Officer Heng Huck Lee, said the company is currently in discussions with two entities in the region to acquire a substantial stake in the companies. The report added that Globetronics Technology was also considering merging with electronic medical manufacturers to expand its business.</p>

26-May Congen Massage Healthcare Club seeking venture capital, to undertake listing in two-three years (Source: China Business News)	Congen Massage Healthcare Club [Kang Jun Yang Sheng], a Chinese privately owned healthcare services provider, is pushing forward its listing plan, Pi Wuling, the Chairman of Kang Chun Investment [Kang Jun Tou Zi] told China Business News. The company is actively looking for venture capital and is scheduled to carry out its listing plan within the next two to three years. It is targeting at annual revenue of CNY 8bn (USD 1.28bn) by 2018.
26-May Computech Holdings signs MoU for disposal of shares in Luck Key Investment to Town Health International	Computech Holdings, the Hong Kong-listed IT services provider, announced that it has signed a memorandum of understanding for the disposal of shares in Luck Key Investment Limited, which is principally engaged in the provision of medical diagnostic and health check services, to listed Town Health International Medical Group for not less than HKD 50m (USD 6.4m).